Transplantation of mesenchymal stem cells (MSCs) into injured or diseased tissue-for the in situ delivery of a wide variety of MSC-secreted therapeutic proteins-is an emerging approach for the modulation of the clinical course of several diseases and traumata. From an emergency point-ofview, allogeneic MSCs have numerous advantages over patient-specific autologous MSCs since "off-the-shelf" cell preparations could be readily available for instant therapeutic intervention following acute injury. Although we confirmed the in vitro immunomodulatory capacity of allogeneic MSCs on antigen-presenting cells with standard coculture experiments, allogeneic MSC grafts were irrevocably rejected by the host's immune system upon either intramuscular or intracerebral transplantation. In an attempt to modulate MSC allograft rejection in vivo, we transduced MSCs with an interleukin-13 (IL13)-expressing lentiviral vector. Our data clearly indicate that prolonged survival of IL13-expressing allogeneic MSC grafts in muscle tissue coincided with the induction of an alternatively activated macrophage phenotype in vivo and a reduced number of alloantigenreactive IFNc-and/or IL2-producing CD8 1 T cells compared to nonmodified allografts. Similarly, intracerebral IL13-expressing MSC allografts also exhibited prolonged survival and induction of an alternatively activated macrophage phenotype, although a peripheral T cell component was absent. In summary, this study demonstrates that both innate and adaptive immune responses are effectively modulated in vivo by locally secreted IL13, ultimately resulting in prolonged MSC allograft survival in both muscle and brain tissue. STEM CELLS 2016;34:1971-1984 
INTRODUCTION
Since their initial characterization by Friedenstein et al. [1] , mesenchymal stem cells (MSCs) have been the subject of intensive research in the field of regenerative medicine. Although the proposed therapeutic applications of MSCs are numerous, three distinct categories can be identified based on the cells' presumed mode of action: direct cell replacement [2] [3] [4] [5] [6] , immunomodulation [7] [8] [9] [10] [11] [12] [13] [14] , and trophic stimulation of endogenous regeneration by (genetically modified) MSC grafts [14] [15] [16] [17] [18] [19] . MSCs can thus be adopted as versatile cell-based delivery vehicles for therapeutic proteins in a wide range of conditions, extending from hematological [13, 20, 21] and cardiovascular [4, 22] disorders to autoimmune [5, 23] and central nervous system (CNS) [7, [14] [15] [16] pathologies. Although both autologous and allogeneic MSCs have been translated into the clinic [12, 13, 24, 25] , the prospect of using universal donor MSCs provides the most attractive alternative, as "off-the-shelf" cell preparations could be readily available for instant therapeutic intervention following acute injury. In addition, autologous patient-derived cells may be compromised due to age or disease [5, 26] . Moreover, the use of allogeneic cells enables the careful selection of (genetically engineered) cell populations displaying maximal effectiveness (i.e., regenerative capacity [27] ) and minimal adverse effects (i.e., tumorigenicity [17] ).
Even though it is widely accepted that MSCs display a range of immunosuppressive properties in vitro [28] [29] [30] , the in vivo immune privileged status of MSCs remains a matter of controversy [25] . Over the years, scientists have often regarded the long-term clinical benefit of allogeneic or xenogeneic MSC transplantation as evidence of their immune privileged character, an assumption only occasionally supported by experiments exploring the fate or in vivo immunogenicity of the transplanted cells [2-5, 10, 11, 13, 31] . In order to safely and effectively apply MSC therapy in disease, it is however of the utmost importance to establish a clear relationship between the in vivo fate of grafted MSCs and the observed clinical response [32] . Biodistribution of the grafted MSCs is a first factor to consider following in vivo cell administration. After intravenous (IV) administration of MSCs, only a very small percentage of the infused MSCs (usually < 1%) reach the target tissue due to cell retention in the lungs, liver, and spleen [22, [33] [34] [35] . Following their entrapment, embolized MSCs release paracrine factors such as tumor necrosis factorstimulated gene 6 (TSG-6) which induce a general state of immune hyporesponsiveness, resulting in an improved therapeutic outcome in inflammation-associated diseases [22, 36, 37] . However, injuries at more distant locations in the body do not always respond equally well to this approach [35, 38] . In these instances, direct cell grafting into (injured) tissue might have a more pronounced therapeutic benefit. MSCs are known producers of immunomodulatory (e.g., interleukin-6 (IL6), IL10, prostaglandin E2 (PGE 2 ), and indoleamine 2,3-dioxygenase (IDO) [9] ), neurotrophic (e.g., brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) [39] ), and angiogenic factors (e.g., vascular endothelial growth factor (VEGF) [40] ). For this reason, their therapeutic application following neurotrauma (e.g., stroke and traumatic brain/spinal cord injury [39, 41] ) and peripheral vascular disease (i.e., ischemia [40] ) can readily be appreciated upon intracerebral (IC) or intramuscular (IM) application, respectively. Immunogenicity is another important determinant of cell fate, especially when allogeneic cells are used. It is imperative to investigate whether allogeneic MSCs have the capacity to survive immunologically for a sufficiently long period of time in order to be of clinical relevance. Eliopoulos et al. [42] were among the first to investigate this matter, describing the presence of alloantigen-reactive CD8 1 T cells, natural killer (NK) T cells, and NK cells following MSC transplantation in major histocompatibility complex (MHC)-mismatched mice. They also found evidence of immunological memory against allografts as repeated MSC transplantations resulted in accelerated graft rejection. Several reports, including our own work, have validated Eliopoulos' findings, additionally describing robust myeloid cell infiltration of allografts and the induction of allograftspecific antibody responses [33, [43] [44] [45] . In the first part of this study, we further elaborated on the immunosuppressive capacities of MSCs in vitro versus in vivo in an effort to unify conflicting literature reports. Although we confirmed the immunomodulatory capacity of allogeneic MSCs on dendritic cells (DCs) using standard in vitro coculture experiments, MSC grafts were rapidly rejected upon IV, IM, or IC transplantation into allogeneic hosts. Furthermore, we found that MSCmediated suppression is cell contact-dependent, as MSCprimed DCs became highly immunostimulatory upon MSC withdrawal. IL13 is a pleiotropic cytokine closely related to IL4 both in structure and in function [46] . These canonical cytokines play overlapping as well as distinct roles during type 2 immunity, and both factors have been found to contribute to the etiology of allergic reactions. Despite their similar biological activities, IL4 signaling in T helper cells promotes Th2 differentiation, whereas T cells are generally unresponsive to IL13 due to the absence of IL13Ra1 expression on their surface [47] . In the second part of this study, we genetically modified allogeneic MSCs with the murine IL13-encoding gene as a potential strategy to modulate allograft-specific immunity and extend in vivo cell graft survival following IM and/or IC transplantation. We focused specifically on IL13 as no evidence has been found to date that this cytokine promotes T cell stimulation or proliferation upon direct exposure, in contrast to IL4 [48] , hence limiting the risk of inducing allergic side effects. In this study, we were able to demonstrate that local secretion of IL13 induced the M2a alternative activation state in graft-infiltrating macrophages (and microglia) and limited the induction of alloreactive CD8 1 T cells. As a result, IL13-mediated modulation resulted in a prolongation of allogeneic cell graft survival in both muscle and brain tissue of immune competent mice.
MATERIALS AND METHODS

Mice
C57BL/6, FVB, and BALB/c mice were purchased from Charles River (Wilmington, MA, http://www.criver.com). Albino C57BL/6, C57BL/6 IL6
2/2
, and FVB ROSA26-L-S-L-Luciferase mice were purchased from Jackson Laboratories (Bar Harbor, ME, http://www.jax.org). All mice, including (C57BL/6 3 FVB) F 1 hybrids, were bred in the animal facility of the University of Antwerp. All experimental procedures were approved by the ethical committee for animal experiments at the University of Antwerp (approval nos. 2011/13 and 2012/39).
Isolation, Genetic Engineering, and Characterization of MSC Cultures
FVB, ROSA26-L-S-L-Luciferase, and BALB/c mouse bone marrowderived MSC cultures were isolated and cultured as previously described by Bergwerf et al. [49] . The following lentiviral vectors (LVs) were used for MSC transduction: pCHMWS-eGFP-T2A-fLuc [50] , pCHMWS-eGFP-IRES-Pac [49] , and pCHMWS-mIL13-IRESPac. LV production was outsourced to the Leuven viral vector core (Molmed, KULeuven, Belgium) [51, 52] . Following LV transduction, Pac-expressing MSCs were selected with puromycin (10 mg/mL; InvivoGen, San Diego, CA, http://www.invivogen. com). For cells transduced with the pCHMWS-eGFP-T2A-fLuc LV, Figure S1 .
Cell Implantation Experiments
All surgical interventions were performed according to previously established procedures [45, 53] . For IC cell injection, mice were anesthetized with a ketamine (80 mg/kg, Pfizer, New York, NY, http://www.pfizer.com) 1 xylazine (16 mg/kg, Bayer, Leverkusen, Germany, http://www.bayer.com) mixture in 0.9% NaCl (Baxter, Deerfield, IL, http://www.baxter.com) and placed in a stereotactic frame (Stoelting, Wood Dale, IL, http://www.stoeltingco.com). 7.5 3 10 4 MSCs (in 2 mL phosphate buffered saline (PBS)) were reproducibly targeted to the right hemisphere, 2.25 mm dextra, and 3.00 mm ventral from bregma. For IM cell injection, mice were anesthetized in an induction chamber using an isoflurane (2.5%) (Forene, AbbottAbbott Park, IL, http://www.abbott.com) 1 N 2 O (1 L/min) 1 O 2 (0.5 L/min) gas mixture, and 5 3 10 5 MSCs or 3 3 10 5 DCs (in 100 mL PBS) were injected in the right (or left) pelvic limb muscle. For IV cell injection, mice were anesthetized using isoflurane (2.5% 1 1 L/ minute N 2 O 1 0.5 L/minute O 2 ) and 7.5 3 10 4 MSCs (in 100 mL PBS) were administered via the tail vein.
In Vivo Bioluminescence Imaging
At different time points between day 1 and day 17 after cell implantation, (albino) C57BL/6 mice were analyzed by realtime in vivo bioluminescence imaging (BLI) to determine the presence of viable cell implants and their biodistribution. Mice were anesthetized using a mixture of isoflurane (Forene, Abbott; 2.5% induction and 2% maintenance) and oxygen. One minute after IV D-luciferin administration (150 mg/kg in PBS; Promega), mice were imaged using a real-time Photon Imager (Biospace Lab, Nesles-la-Vall ee, France, http://www. biospacelab.com) or an IVIS Spectrum imaging system (Caliper Life Sciences, Hopkinton, MA, http://caliperls.com was recently acquired by PerkinElmer, Waltham, MA, http://www. perkinelmer.com). Data were acquired and analyzed with M3Vision (Biospace Lab) or Living Image (Caliper) software.
Functional Analysis of Splenic DCs
Spleens were digested with collagenase type III (Worthington Biochemicals, Lakewood, NJ, www.worthington-biochem.com), further dissociated in Ca 21 -free medium, and separated into high and low density fractions on a Nycodenz gradient (Nycomed, Asker, Norway, http://www.nycomed.com was recently acquired by Takeda Pharmaceuticals, Z€ urich, Switzerland, http://www.tpi. takeda.com). Low density cells were retrieved from the interphase, and DCs were enriched by magnetic separation with CD11c MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany, http:// www.miltenyibiotec.com). For all isolations, > 90% DC purity was achieved, as determined by antibody staining with phycoerythrinlabeled anti-mouse CD11c (12-0114; eBioscience, San Diego, CA, http://www.ebioscience.com) and measurement with an Epics XL-MCL analytical flow cytometer (Beckman Coulter). Following isolation, DCs were either cultured alone or brought in coculture with FVB MSCs or FVB MSCs-IL13 (ratio 2:1 or 5:1 for ELISA or DC vaccination experiments, respectively). For subsequent ELISA, 1 mg/mL lipopolysaccharide (LPS; InvivoGen) 1 500 U/mL interferon-g (IFNg; ImmunoTools, Friesoythe, Germany, http://www.immunotools.de) was added to the cell cultures, and supernatants were harvested 24 hours later. MSC-DC supernatants were tested for the presence of various cytokines using the following murine ELISAs: tumor necrosis factor alpha (TNFa) (BioLegend, San Diego, CA, http://www.biolegend.com), IL4 (Peprotech), IL6 (BioLegend), IL10 (eBioscience), and IL13 (Peprotech). For DC vaccination experiments, cell cultures were supplemented with 20 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) (ImmunoTools). Following 48 hours of coculture, DCs were harvested and resuspended at a concentration of 3 3 10 5 cells per 100 mL PBS for IM vaccination in C57BL/6 mice.
Detection of Alloantigen-Specific T Cell Responses
Two weeks after MSC grafting or DC vaccination, spleens were surgically removed and dissociated over a 70 mm nylon mesh. After density-based centrifugation (Ficoll-Paque Plus; GE Healthcare, Little Chalfont, United Kingdom, http://www3.gehealthcare. com), T cells were enriched by magnetic separation with mouse CD4, CD8a, or CD90.2 MicroBeads (Miltenyi Biotec). Isolated T cell populations were seeded in 96-well round-bottom or ELISpot plates under the following conditions: (a) no stimulation, (b) general stimulation: phorbol 12-myristate 13-acetate (PMA) (50 ng/ mL, Sigma-Aldrich, Saint Louis, MO, https://www.sigmaaldrich. com) 1 ionomycin (500 ng/mL, Sigma-Aldrich), and (c) antigenspecific stimulation: MSCs (ratio 10:1) or DCs (ratio 10:1).
For subsequent flow cytometric analysis, CD90.2 1 cells were stimulated for 4 hours at 37 8C in the presence of monensin (0.67 mL/mL GolgiStop; BD Biosciences, San Diego, CA, http:// www.bdbiosciences.com), and intracellular cytokine staining was performed on the cells using the antibodies listed in Supporting Information Table 1 . T cell cytokine production was measured on a FACSAria II cell sorter and analyzed using the FACSDiva software (both BD Biosciences). A detailed visualization of the gating strategy used to determine the percentages of CD4 1 and CD8
1
T cells producing the cytokines IL2, IFNg, IL4, and IL17 is provided in Supporting Information Figure S2 . For subsequent ELISpot analysis, CD8 1 T cells were stimulated for 16 hours at 37 8C
and used in a murine IFNg ELISpot assay (Diaclone, Besançon, France, http://www.diaclone.com). For IFNg ELISA, CD4 1 and CD8 1 T cells were stimulated for 16 hours at 37 8C. Supernatants were collected and analyzed with the murine IFNg ELI-pair (Diaclone) according to the manufacturer's protocol.
Detection of Allograft-Specific Antibody Responses
FVB MSCs were preincubated with whole serum (1:6 dilution) derived from control, FVB MSC-, or FVB MSC-IL13-grafted mice and stained using labeled isotype-specific secondary antibodies, listed in Supporting Information 
Histological Analysis
Mice were deeply anesthetized with an intraperitoneal injection of 60 mg/kg pentobarbital (Nembutal; Ceva Sant e Animale, Libourne, France, http://www.ceva.com), transcardially perfused with 0.9% NaCl, and perfused-fixed with 4% paraformaldehyde. Whole brain/pelvic limb muscles were surgically removed and postfixed in 4% paraformaldehyde. Fixed tissues were freeze-protected with a sucrose gradient, snap-frozen in liquid nitrogen, and 10 mm thick cryosections were made. Immunofluorescent staining was performed according to previously optimized procedures [53, 54] using the antibodies listed in Supporting Information Table 1 . Stained slides were mounted with Prolong Gold antifade reagent (Life Technologies, Rockville, MD, http://www.lifetech.com), and images were acquired using an Olympus BX51 fluorescence microscope equipped with an Olympus DP71 digital camera. Olympus cellSens Dimension software was used for image acquisition and processing (Olympus, Tokyo, Japan, http://www.olympus-global.com).
In Vivo LV Injection Experiments
The following LVs were used for in vivo administration: pCHMWS-mIL13-IRES-Pac and pCHMWS-BFP-IRES-Pac [55] . All surgical interventions were performed according to previously established procedures [56] . Briefly, C57BL/6 mice (8 weeks of age) were anesthetized with a ketamine (75 mg/kg; Eurovet, Bladel, The Netherlands (no website found) was recently acquired by Dechra Pharmaceuticals, Northwich, United Kingdom, http:// www.dechra.com) 1 medetomidine (1 mg/kg; Pfizer) mixture in 0.9% NaCl (Baxter) and placed in a stereotactic frame (Stoelting). 2 mL of LV concentrate (1.5 3 10 7 -3 3 10 7 pg/mL p24) was reproducibly targeted to the splenium of the corpus callosum at 1.6 mm posterior and 0.3 mm dextra from bregma and 1.1 mm ventral from the dura. Anesthesia was reversed with an intraperitoneal injection of atipamezole (0.5 mg/kg; Pfizer).
Induction of Cuprizone-Associated Inflammatory CNS Lesions
At the age of 8 weeks, mice with or without prior LV injection received standard rodent chow mixed with 0.2% w/w cuprizone (CPZ; Sigma-Aldrich) for a period of 4 weeks in order to induce neuroinflammation and CNS demyelination, as previously described [56] [57] [58] [59] .
Statistical Analysis
All numeric outcome variables were tested for normality and, if needed, log-transformed to obtain an approximately normal distribution. The following statistical tests were used: (a) one-way ANOVA for TNFa/IL6 ELISA data and for the flow cytometric detection of antibody responses, (b) generalized linear mixed modeling for the flow cytometric detection of T cell cytokine production, (c) two-way ANOVA or one-way ANOVA with subsequent independent t-test for IFNg ELISpot data, (d) linear mixed modeling for IFNg ELISA data and in vivo bioluminescence, and (e) Mantel-Cox testing for in vivo cell survival analysis. When required, post hoc analyses were performed and resulting p values were adjusted using a Tukey correction for multiple testing. The Mantel-Cox test was performed using GraphPad Prism All remaining statistical analyses were performed using the statistical package R version 3.1.2. p values < .05 were considered statistically significant: *, p < .05; **, p < .01; ***, p < .001; n.s., not significant.
RESULTS
Allogeneic MSCs Are Subject to Immune Recognition In Vivo, Despite Their Immunomodulatory Properties In Vitro
In the first part of this study, we assessed the immunological properties of allogeneic MSCs in vitro versus in vivo. Coculture experiments of FVB mouse-derived MSCs ( Fig. 1: FVB MSC) with LPS/IFNg-activated C57BL/6 splenic DCs confirmed the in vitro immunomodulatory capacity of MSCs, illustrated by a reduction in TNFa secretion by DCs ( Fig. 2A) and an elevation in IL6 production by MSCs (Fig. 2B) . In contrast, grafted luciferase/ eGFP-expressing FVB MSCs (Fig. 1 : FVB MSC-Luc/eGFP a ) rapidly became undetectable by in vivo BLI following IV, IM, and IC implantation in C57BL/6 mice (Fig. 2C) . IV administration of FVB MSCs-Luc/eGFP a resulted in cell entrapment in the lungs followed by rapid loss of the BLI signal. IM and IC MSC allografts, on the other hand, could be detected-with decreasing signal intensity-up to 1 week postinjection at their original site of implantation. Additionally, we investigated whether FVB allograft-specific T cell responses were induced upon MSC infusion via these different administration routes (Fig. 2D, 2E ). In agreement with and further extending our preceding observations [45] , substantial numbers of IFNg T cell responses (Th1/Th2) and Th17/Tc17 responses were not detected in any of the tested conditions (Supporting Information  Fig. S3 ). The induction of alloantigen-reactive CD8 1 T cells following IM administration of MSCs was additionally confirmed by means of IFNg ELISpot and ELISA (Supporting Information Fig. S4 ).
In Vitro MSC-Primed DCs Become Highly Immunostimulatory, Both In Vitro and In Vivo, Upon Withdrawal of MSC Contact
In the previous paragraph, we described seemingly contradictory effects of allogeneic MSCs in vitro versus in vivo: even though they had an immunomodulatory effect on DC function under in vitro conditions ( Fig. 2A) , a manifest induction of MSCspecific T cells was observed upon their IM implantation in an allogeneic host (Fig. 2D, 2E) . In order to further investigate this discrepancy, we examined whether MSC-primed DCs displayed a reduced T cell stimulatory capacity in vitro upon withdrawal of MSC contact. Splenic DCs were isolated from (C57BL/ 6 3 FVB) F 1 mice, cocultured in vitro with FVB MSCs, and used to restimulate CD8 1 T cells isolated from naive or FVB MSCgrafted C57BL/6 mice in an IFNg ELISpot assay (Fig. 3A) . Using this experimental setup, we found no reduction in the T cell stimulatory capacity of MSC-primed DCs, compared to unprimed DCs, upon withdrawal of MSC contact. In a subsequent experiment, we studied the in vivo T cell induction capacity of MSC-primed DCs. Splenic DCs from (C57BL/6 3 FVB) F 1 mice, either unprimed or primed with FVB MSCs, were injected intramuscularly into C57BL/6 mice. An IFNg ELISpot assay using CD8 1 T cells from these injected mice revealed the efficient induction of FVB alloantigen-specific CD8 1 T cell responses following DC vaccination, regardless of prior MSC priming (Fig. 3B) . Surprisingly, MSC-primed DCs induced even more alloreactive T cells in vivo than unprimed DCs. Upon withdrawal of MSC contact, in vitro MSC-primed DCs thus became highly immunostimulatory, supporting the notion that MSCmediated modulation is cell contact-dependent [29] .
Genetic Engineering of MSC Allografts with IL13 Reduces the Induction of Peripheral Allograft-Specific T Cell Responses
Since allogeneic MSCs were found to elicit a significant T cell response upon IM transplantation, we investigated whether the neoexpression of IL13 by allogeneic MSCs could (partially) counteract this induction of alloreactive T cells following IM MSC transplantation. To this end, we evaluated the occurrence of allograft-specific T cell responses in C57BL/6 mice 2 weeks after IM transplantation of control FVB MSCs or IL13-producing FVB MSCs ( Fig. 1: FVB MSC-IL13 ). Both transplant groups displayed significant allograft-specific CD8 1 T cell responses, although mice with IL13-producing allografts were characterized by significantly fewer IFNg 1 and IL2 1 CD8 1 T cells (Fig. 4A, 4B ). Similarly to the aforementioned results, allograft-specific CD4 1 T cell responses, as well as Th17/Tc17 responses, were not detected in any of the experimental groups (Supporting Information Fig. S5 ). As T cells lack a functional IL13 receptor on their cell surface [47] , it is highly unlikely that IL13 exerts its effect on T cell functionality at the level of the T cells themselves. Indeed, when T cells isolated from FVB MSC-grafted mice were restimulated in vitro with either FVB MSCs or FVB MSCs-IL13, no difference in IFNg production by isolated CD8 1 T cells was seen (Fig. 4C) . Conditions in which
MSCs had been precultivated in the well for 24 hours prior to coculture were included to ensure a sufficiently high IL13 concentration throughout MSC-T cell interaction. Although IFNg production by CD8
1 T cells was elevated in the latter, primed T cells were not influenced by the presence of IL13 in the supernatant. In agreement with our other results, IFNg production by CD4 1 T cells was not detected (Fig. 4D ).
Short-Term In Vitro IL13-Priming of DCs Cannot
Recapitulate Complex In Vivo Interactions Between Allogeneic MSCs, IL13, Antigen-Presenting Cells, and T Cells
As IL13 has been shown to effectively reduce the induction of peripheral T cell responses without acting directly on activated T cells, we hypothesized that the cytokine must exert its effect at the level of antigen-presenting cells (APCs). Like nonengineered MSCs, IL13-expressing MSCs reduced TNFa production by DCs ( Fig. 2A) and are induced to produce IL6 upon DC coculture (Fig.  2B) . Unexpectedly, in vitro IL13-primed C57BL/63FVB DCs did not display a reduced T cell stimulatory capacity in vitro (Fig. 3A ) or in vivo (Fig. 3B ) in comparison to nonengineered MSCs. Clearly, the intricate mechanism(s) by which IL13 modulates allospecific T cell responses in vivo are far too complex to be simulated in vitro.
IL13-Mediated T Cell Modulation is Restricted to Alloantigens Present at the Site of IL13 Secretion and Does Not Coincide with Changes in Allograft-Specific Antibody Response
Next, we questioned whether IL13 only modulated the alloimmune response directed toward the IL13-expressing FVB MSC allograft or whether MSC-derived IL13 could additionally modulate alloimmune responses directed toward a distant, third-party allograft. To investigate this, C57BL/6 mice received a BALB/c MSC allograft ( Fig. 1 : BALB/c MSC) in the left hind limb and, if applicable, an additional FVB MSC or FVB MSC-IL13 allograft in the right hind limb. Using this setup, we validated the finding that the percentage of FVB alloantigen-specific IFNg-and IL2-producing CD8 1 T cells was significantly reduced in mice with an IL13-producing MSC graft compared to mice with a control MSC graft (Fig. 4E, 4F and Supporting Information Fig. S6 ). Interestingly, the relative number of BALB/c alloantigen-specific IFNgand IL2-producing CD8 1 T cells was comparable in all BALB/c MSC-grafted mice, regardless of the presence of an additional FVB MSC(6IL13) graft. This thus suggests that the observed IL13-mediated immunomodulation is restricted to FVB MSC antigens, that is, alloantigens present at the site of IL13 secretion and does not suppress immune responses against distant thirdparty allografts. Finally, we investigated the potential of MSCderived IL13 to modulate allograft-specific antibody responses. Two weeks after IM transplantation of FVB MSCs or FVB MSCs-IL13, whole serum was collected from transplanted or naive C57BL/6 mice and evaluated for the presence of allograftspecific antibodies (Fig. 4G) . FVB MSC-specific antibodies of the IgG isotype-but not of the IgA, IgD, IgE, and IgM isotypescould readily be detected in all transplanted mice. No modulatory effect of IL13 on the antibody response was observed as comparable levels of graft-specific IgG antibodies were found in mice grafted with nonengineered or IL13-expressing MSCs.
Transplantation of IL13-Producing MSCs Induces an Alternatively Activated Phenotype in Graft-Infiltrating Macrophages
As IL13 is a key cytokine in the promotion of alternative macrophage activation [46] , we examined whether IL13-producing MSC allografts were able to induce an alternatively activated phenotype in graft-infiltrating macrophages (and microglia in the case of IC grafts [55] ). Histological analyses of FVB MSC-Luc/eGFP b grafts ( Fig. 1 : FVB MSC-Luc/eGFP b ) and FVB MSC-Luc/eGFP/IL13 grafts ( Fig. 1 : FVB MSC-Luc/eGFP/IL13) were performed at 5 (IM grafts) or 7 (IC grafts) days after implantation in C57BL/6 mice. At given time points, all eGFP-expressing MSC grafts-or remnants thereof in case of IC FVB MSC-Luc/eGFP b transplantation-could readily be detected (Fig. 5, first row) . MSC allografts displayed a substantial infiltration of activated macrophages (and microglia) under all experimental conditions, as demonstrated by the presence of Iba1 1 and F4/80 1 myeloid cells within and surrounding MSC grafts (Fig. 5, second-fourth rows) . The classic activation marker MHCII was expressed by graft-infiltrating F4/80 1 macrophages (and microglia) in all tested conditions (Fig. 5, third and fifth rows). In contrast, the expression of Arg1, a marker of alternative M2a activation [46, 60] , was exclusive to F4/80 1 macrophages (and microglia) infiltrating IL13-producing grafts (Fig. 5 , fourth and fifth rows). Similarly, the expression of Ym1 and FIZZ1, two additional M2a markers [46] , was restricted to myeloid cells associated with IL13-producing MSC grafts (Fig. 5, sixth row) . Graft-infiltrating CD3 1 and CD8 1 T cells were observed under all experimental conditions (Fig. 5 , seventh and eighth rows).
IL13 Alone is Sufficient to Induce In Vivo M2a Macrophage/Microglia Polarization
In a subsequent experiment, we investigated whether the in vivo M2a polarization of macrophages and microglia observed following grafting of IL13-expressing MSCs is induced by the single action of IL13 or by a combined effect of MSCs and IL13. For this, we examined whether expression of IL13 in the splenium of the corpus callosum could induce alternative M2a polarization of microglia and macrophages following CPZ administration, a well-established mouse model of neuroinflammation [56, 61] . As shown in Figure 6 , CPZ administration leads to severe accumulation of F4/80 1 microglia/macrophages in the splenium of non-injected control mice, blue fluorescent protein (BFP)-expressing control LV-injected mice and IL13-expressing LV-injected mice. In vivo administration of IL13-expressing LV additionally induced Arg1 expression in CPZ lesion-associated microglia/macrophages, indicating that IL13 alone can effectively induce M2a microglia/macrophage polarization.
IL13 Prolongs MSC Allograft Survival Upon IM and IC Administration
In a final experiment, we investigated whether the production of IL13 by MSCs could alter the course of MSC allograft rejection. To this end, the in vivo survival of FVB MSC-Luc/eGFP b and FVB MSC-Luc/eGFP/IL13 allografts was evaluated noninvasively by quantitative in vivo BLI following IM (Fig. 7A-7C ) and IC ( Fig. 7D-7F ) implantation in albino C57BL/6 mice. Allograft survival, defined as the time point beyond which the bioluminescent signal was equal to or lower than background radiance, was modestly-albeit statistically significantlyextended for IL13-producing MSCs following IM implantation (Fig. 7B, 7C ). This was also true following IC implantation, with an even more pronounced graft survival-promoting effect of IL13 in these animals (Fig. 7E, 7F ). In conclusion, these data illustrate that IL13 can delay the course of allograft rejection in both muscle and brain tissue. 
DISCUSSION
To this day, immune recognition of allografts remains the major hurdle in achieving successful allogeneic cell transplantation, and thus, sustained therapeutic benefit of allogeneic cellular therapies. Correspondingly, we observed that transplantation of MSCs, cells with an established in vitro immunomodulatory potential [28] [29] [30] , into allogeneic hosts irrevocably resulted in allograft rejection. Furthermore, IM MSC transplantation triggered the induction of graft-specific CD8 1 T cells in allogeneic hosts. Alloreactive T cells can be sensitized via three distinct pathways: direct, indirect, and semidirect allorecognition [62, 63] . Following in vitro IFNg stimulation, MSCs have been found to upregulate MHCII expression and display some antigenpresenting properties in the context of direct allorecognition [64] . Histological analysis of the graft sites however did not (Fig. 5, third and fifth rows). In contrast, indirect allorecognition of MSCs is likely to occur, albeit at a slower rate, accounting for only <10% of the alloreactive T cell repertoire during acute rejection [65] . Particularly in the case of fully MHC-mismatched cell grafts, this process will require a more complex sequence of events to achieve effective allograft elimination [66] . Consequently, we believe that the semidirect pathway of allorecognition is the most likely mechanism to explain the rapid induction of allograft-specific T cell responses following transplantation of fully MHC-mismatched MSCs [62] . Furthermore, there is compelling evidence that innate immune cells are also capable to distinguish between self and allogeneic non-self [67, 68] . Since the transplanted cells used in this study were fully incompatible with their recipients, it is likely that multiple allorecognition mechanisms jointly contributed to the observed allograft rejection.
In our opinion, distinct allograft recognition mechanisms may be responsible for the rejection of IM and IC allografts, illustrated by their differential capacity to induce alloreactive T cells. Even so, histological analysis revealed the presence of CD8 1 T cells in both IM and IC allografts. Given the absence of alloreactive T cells in secondary lymphoid organs after IC transplantation of allogeneic MSCs, it is safe to assume that CD8 1 T [33] , as they found that intraperitoneal MSC allografts survived in BALB/c nude mice but not in fully competent BALB/c recipients. Consequently, it is expected that at least some of the T cells infiltrating IM allografts are alloreactive and actively contribute to allograft rejection. The ultimate goal of our study was to modulate these existing allorecognition mechanisms in vivo, in favor of MSC allograft survival. Upon transduction with an IL13-expressing LV, we found that local IL13 production by MSC allografts induced an alternatively activated phenotype in graft-infiltrating macrophages (and microglia). Although macrophages can adopt a myriad of distinct phenotypes in response to different stimuli, nonresting macrophages are generally classified as either "classically" (M1) or "alternatively" (M2) activated. MHCII is typically upregulated upon macrophage activation (in both M1-and M2-oriented cells), whereas additional expression of the enzymes Arg1, Ym1, and FIZZ1 is indicative of the M2a phenotype [46, 60] . In our study, induction of the M2a macrophage/microglia phenotype was a direct effect of MSC-derived IL13, as IC injection of an IL13-encoding LV into inflammatory CNS lesions was similarly found to induce Arg1 expression in macrophages/microglia (Fig. 6) . Furthermore, we report that this IL13-driven shift in macrophage (and microglia) phenotype coincides with reduced peripheral T cell responses following IM transplantation of allogeneic MSCs. Interestingly, elevated Arg1 expression by macrophages has previously been associated with decreased T cell function [69, 70] . Rodriguez and colleagues found that macrophages stimulated with IL4 1 IL13 upregulated their expression of Arg1 and cationic amino acid transporter 2B, causing a rapid drop in extracellular Larginine levels. Due to this depletion, CD3f chain expression was lost on activated T cells, resulting in impaired T cell proliferation and decreased cytokine production. Similarly, we postulate that IL13-induced M2a macrophages migrate to secondary lymphoid organs-to exert their role as APCs-where they locally deplete the environment of L-arginine and cause impaired T cell function, thus recapitulating our flow cytometry results (Fig. 4A, 4B , 4E, 4F). Alternatively, M2a macrophages might display a reduced migratory capacity towards secondary lymphoid organs, and/or IL13-conditioned M2a macrophages (and microglia) might display a reduction in innate effector functions (such as direct allograft killing), although these hypotheses remain to be investigated. Nevertheless, we postulate that MSC allograft rejection is predominantly mediated by the direct action of macrophages (and microglia). In the case of IM MSC transplantation, the allograft rejection process may additionally be aided by alloreactive T cells. But regardless of the relative contributions of these different allorecognition mechanisms, it is evident that IL13 has the potential to modulate both innate and adaptive immune mechanisms, ultimately resulting in extended MSC allograft survival.
When considering possible applications of IL13-overexpressing MSCs, one should take into account that allograft-survival was only modestly prolonged by MSC-derived IL13. Although this excludes applications in which sustained MSC survival is recommended, for example, long-term production of therapeutic proteins such as erythropoietin or factor VIII [71, 72] , models which predominantly rely on the supportive and regenerative functions of MSCs for disease improvement may still benefit from a slightly extended therapeutic window of allogeneic MSC grafts. For example, the beneficial effects of allogeneic MSCs in ischemic stroke were still apparent 14 days after cell administration, even though just a fraction of transplanted cells is expected to persist at this point [37] . It is therefore safe to assume that a prolongation of the grafted MSCs' therapeutic period will go hand in hand with an improved therapeutic outcome.
CONCLUSION
In conclusion, this study demonstrates that locally secreted IL13 modulates allograft-specific immunity by promoting the M2a activation state in graft-infiltrating macrophages and by limiting the induction of allograft-specific CD8
1 T cell responses. This IL13-mediated modulation resulted in a prolongation of allogeneic MSC survival in both muscle and brain tissue. Aside from transplantation research, the pleiotropic effects IL13 further encourage the application of this cytokine for the relief of acute or chronic inflammation in models of trauma or disease.
